Inhibitors of tissue-nonspecific alkaline phosphatase (TNAP): From hits to leads

Methods in Molecular Biology

Volumn 1053, Issue , 2013, Pages 85-101

  Teriete, Peter ^a   Pinkerton, Anthony B ^a   Cosford, Nicholas D P ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Absorption; distribution; excretion; High throughput screening (HTS); Hit to lead; Inhibitor design; Medicinal chemistry; metabolism; Pharmacokinetics (PK); Pharmacophore; Rational design; Structure activity relationship (SAR); toxicity (ADME T)

Indexed keywords

ALKALINE PHOSPHATASE; ENZYME INHIBITOR; PYRAZOLE DERIVATIVE;

ALGORITHM; ARTICLE; COLORIMETRY; DRUG BINDING; DRUG SCREENING; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; IC 50; METHODOLOGY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALKALINE PHOSPHATASE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881097816     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-562-0_5     Document Type: Article

References (28)

1. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185
2. Bleicher KH, Bohm HJ, Muller K et al (2003) Hit and lead generation: Beyond highthroughput screening. Nat Rev Drug Discov 2:369-378
3. Sidique S, Ardecky R, Su Y et al (2009) Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecifi c alkaline phosphatase (TNAP). Bioorg Med Chem Lett 19:222-225
4. Barh D, Ahmad S, Bhattacharjee A (2012) In silico and ultrahigh-Throughput screenings (uHTS) in drug discovery: An overview. Pharmaceutical biotechnology. Wiley-VCH Verlag, Weinheim, Germany, pp 451-490
5. Zoete V, Grosdidier A, Michielin O (2009) Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med 13:238-248
6. Baell JB, Holloway GA (2010) New substructure fi lters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-2740
7. Pinkerton AB, Vernier J-M, Cube RV, Hutchinson JH (2006) Inventor Heterocyclic indanone potentiators of metabotropic glutamate receptors. USA WO Patent WO/2006/047237
8. Sergienko E, Su Y, Chan X et al (2009) Identifi cation and characterization of novel tissue-nonspecifi c alkaline phosphatase inhibitors with diverse modes of action. J Biomol Screen 14:824-837
9. Sergienko EA, Millan JL (2010) Highthroughput screening of tissue-nonspecifi c alkaline phosphatase for identifi cation of effectors with diverse modes of action. Nat Protoc 5:1431-1439
10. Kerns EH, Di L, Carter GT (2008) In vitro solubility assays in drug discovery. Curr Drug Metab 9:879-885
11. John S, Thangapandian S, Arooj M et al (2011) Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors. BMC Bioinformatics 12 Suppl 14, S4
12. Binns M, de Visser SP, Theodoropoulos C (2012) Modeling fl exible pharmacophores with distance geometry, scoring, and bound stretching. J Chem Inf Model 52:577-588
13. Tai W, Lu T, Yuan H et al (2011) Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors. J Mol Model 1-14
14. Arnold K, Bordoli L, Kopp J et al (2006) The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics 22:195-201
15. Kozlenkov A, Le Du MH, Cuniasse P et al (2004) Residues determining the binding specifi city of uncompetitive inhibitors to tissue-nonspecifi c alkaline phosphatase. J Bone Miner Res 19:1862-1872
16. Taha MO, Bustanji Y, Al-Bakri AG et al (2007) Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. J Mol Graph Model 25:870-884
17. Zampieri D, Mamolo MG, Laurini E et al (2009) Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. J Med Chem 52:5380-5393
18. Kariv I, Cao H, Oldenburg KR (2001) Development of a high throughput equilibrium dialysis method. J Pharm Sci 90:580-587
19. Kansy M, Senner F, Gubernator K (1998) Physicochemical high throughput screening: Parallel artifi cial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010
20. Dahl R, Bravo Y, Sharma V et al (2011) Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem 54: 3661-3668
21. Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449
22. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44: 235-249
23. Banker MJ, Clark TH et al (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974
24. Di L, Kerns EH et al (2008) Applications of high throughput microsomal stability assay in drug discovery. Comb Chem High Throughput Screen 11:469-476
25. Guengerich FP (1989) Oxidation of halogenated compounds by cytochrome P-450, peroxidases, and model metalloporphyrins. J Biol Chem 264:17098-17205
26. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
27. Korfmacher WA, Cox KA et al (2001) Cassette-Accelerated rapid rat screen: A systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun Mass Spectrom 15: 335-340
28. Mei H, Korfmacher WA et al. (2006) Rapid in vivo oral screening in rats: Reliability, acceptance criteria, and fi ltering effi ciency. AAPS J 8:E493-500